183 related articles for article (PubMed ID: 23525279)
1. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
2. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Alt J; Stathis M; Rojas C; Slusher B
FASEB J; 2013 Jul; 27(7):2620-5. PubMed ID: 23525278
[TBL] [Abstract][Full Text] [Related]
3. S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation.
Lee SK; Kim H; Cheong YH; Kim MJ; Jo SA; Youn HS; Park SI
Biochem Biophys Res Commun; 2013 Sep; 438(4):765-71. PubMed ID: 23891752
[TBL] [Abstract][Full Text] [Related]
4. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Kim MJ; Chae SS; Koh YH; Lee SK; Jo SA
FASEB J; 2010 Nov; 24(11):4491-502. PubMed ID: 20624932
[TBL] [Abstract][Full Text] [Related]
5. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Klusák V; Barinka C; Plechanovová A; Mlcochová P; Konvalinka J; Rulísek L; Lubkowski J
Biochemistry; 2009 May; 48(19):4126-38. PubMed ID: 19301871
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide.
Conway RE; Rojas C; Alt J; Nováková Z; Richardson SM; Rodrick TC; Fuentes JL; Richardson NH; Attalla J; Stewart S; Fahmy B; Barinka C; Ghosh M; Shapiro LH; Slusher BS
Angiogenesis; 2016 Oct; 19(4):487-500. PubMed ID: 27387982
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
8. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
9. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of human glutamate carboxypeptidase III.
Hlouchová K; Barinka C; Klusák V; Sácha P; Mlcochová P; Majer P; Rulísek L; Konvalinka J
J Neurochem; 2007 May; 101(3):682-96. PubMed ID: 17241121
[TBL] [Abstract][Full Text] [Related]
11. An aminopeptidase from Streptomyces sp. KK565 degrades beta amyloid monomers, oligomers and fibrils.
Yoo C; Ahn K; Park JE; Kim MJ; Jo SA
FEBS Lett; 2010 Oct; 584(19):4157-62. PubMed ID: 20828565
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II.
Barinka C; Rinnová M; Sácha P; Rojas C; Majer P; Slusher BS; Konvalinka J
J Neurochem; 2002 Feb; 80(3):477-87. PubMed ID: 11905994
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
Mlcochová P; Plechanovová A; Barinka C; Mahadevan D; Saldanha JW; Rulísek L; Konvalinka J
FEBS J; 2007 Sep; 274(18):4731-41. PubMed ID: 17714508
[TBL] [Abstract][Full Text] [Related]
15. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Navrátil M; Tykvart J; Schimer J; Pachl P; Navrátil V; Rokob TA; Hlouchová K; Rulíšek L; Konvalinka J
FEBS J; 2016 Jul; 283(13):2528-45. PubMed ID: 27208881
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
17. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.
Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A
J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867
[TBL] [Abstract][Full Text] [Related]
18. Design of Peptide Substrate for Sensitively and Specifically Detecting Two Aβ-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.
Chen PT; Chen CL; Lin LT; Lo CH; Hu CJ; Chen RP; Wang SS
PLoS One; 2016; 11(4):e0153360. PubMed ID: 27096746
[TBL] [Abstract][Full Text] [Related]
19. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.
Barinka C; Mlcochová P; Sácha P; Hilgert I; Majer P; Slusher BS; Horejsí V; Konvalinka J
Eur J Biochem; 2004 Jul; 271(13):2782-90. PubMed ID: 15206943
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay.
Rojas C; Frazier ST; Flanary J; Slusher BS
Anal Biochem; 2002 Nov; 310(1):50-4. PubMed ID: 12413472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
